Once-yearly infusions of rituximab are as effective as twice-yearly dosing for sustained control of MS in a new phase 3 trial ...

CD20 is a potential target for the treatment of leukemia, lymphoma, and some autoimmune diseases. However, due to the complexity of expression and the unstable bioactivity, it is very hard to find an ...

Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to ...

Sonrotoclax has received breakthrough therapy designation for relapsed/refractory mantle cell lymphoma after BTK inhibitor ...

Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to ...

CD20 expression levels correlate with outcomes in B-cell lymphoma patients treated with CD20xCD3 bispecific antibodies. Patients with reduced CD20 expression had significantly lower PFS and OS rates ...

Slingshot Biosciences ("Slingshot") today announced two additions to its TruCytes™ cell mimic product line designed to ...

Therapeutic monoclonal antibodies (mAbs) are used in chronic lymphocytic leukemia immunotherapies to target the receptor CD20 at the plasma membrane of immunological B cells. Although they have been ...

Anti-CD20 monoclonal antibodies are a class of therapeutic antibodies that target a specific protein called CD20 found on the surface of B cells, a type of white blood cell. These antibodies are ...

Prospective Randomized Trial of Melphalan and Prednisone Versus Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Primary Systemic Amyloidosis PURPOSE: To ...

You have full access to this article via your institution. In summary, we performed a FACS-based genome-scale shRNA screen for coding genes in a Burkitt’s lymphoma cell line model, which identified 37 ...

As East Asia prepares to shut down for the Lunar New Year holiday and looks towards the Year of the Snake, it’s time to look back at bitcoin BTC $122,672.68 and the CoinDesk 20 (CD20)’s performance ...